FMT may be safe for immunocompromised patients with C. difficile
October 14, 2013
SAN DIEGO – Colleen Kelly, MD, clinical assistant professor of medicine at Brown Alpert School of Medicine in Providence, RI, discusses her presentation, “Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium difficile Infection (CDI) in Immunocompromised Patients,” at the American College of Gastroenterology Annual Scientific Meeting.
In a retrospective study of 61 adult and five pediatric patients with C. difficile infection treated with FMT, the researchers observed an 89% overall cure rate, with few related or serious adverse events and no infectious complications.